UK Markets close in 7 hrs 30 mins

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
85.81+0.17 (+0.20%)
At close: 4:03PM EDT
Sign in to post a message.
  • J
    Joe
    And Merck would know! They used a modified herpes vaccine injected directly into my tumors to get my immune system to respond aggressively along with 2 yrs of keytruda and I had aggressive stage 4 cancer tumors were literally everywhere-healthy as a horse today 3 yrs and few months after first diagnosis thank you Merck and thank God!
  • e
    exNKTR
    Unidentified Analyst

    Very good. Well, I wanted to say that we're going to extend the time to speak for another five minutes simply because we got started a little bit late. I did want to cover pipeline opportunities. So, I thought it would be appropriate to discuss MK-4482, the Ridgeback oral antiviral. Just a couple questions, please, Roger. First, when should we expect the Phase 2 data? I'm assuming that you'll want to publish that to be able to ensure rapid enrollment once you kick off Phase 3, and then second, I noticed that there were some clinicaltrials.gov changes just in the last few days. I believe that one study took out the high dose, any color that you can provide to help us understand where you are, and how you'd like to characterize that product opportunity?

    Ken Frazier

    Yes, David, thank you. So, I'm very enthusiastic about MK-4482. I think in the near-term, we all recognize that if there were potent antiviral drugs, directed against SARS, SARS-CoV-2. COVID-19, antiviral is a viral mediated disease to get rid of the virus early enough anyway, you get rid of the disease. So that it offers great promise provided you can get in early enough with something that people can take. I think that the challenge thus far with, for example, Remdesivir is -- okay, the drug has to be given intravenously. Obviously, that is in a hospitalized setting it tends to get them late. We know from prior experience that in just from first principles that if you're going to treat a viral mediated disease, you'd like to get in from the earliest moment of infection, or indeed from a prophylactic point of view, even that would be better.

    4482 is an analogue of Ribonucleotide, it is incorporated into the RNA that is produced by the unique viral enzyme, the RNA dependent RNA polymerase, and that is part of the replication of the virus that enables the virus to make more of itself, when it is incorporated, as a result causes errors in the genetic code of the virus, and those errors accumulate and the phenomenon is called error catastrophe. It's not the first drug that works by this mechanism, but it's a very powerful mechanism, because there is with appropriate drug levels, there is just more and more miss incorporation and you fairly rapidly see viral copies disappeared, because they're not functional anymore. They don't encode the virus as opposed to be, and that's effective when you look in cell lines, and it's effective when you look in animals, and our Phase 1 studies, which were, of course, initiated by Ridgeback, and we've been acquired our interest in this. Phase 1 studies have demonstrated that the compound can be administered in a five-day course, it is well-tolerated, and we achieve levels of drug that should be associated with inhibition of the replication of the virus through this mechanism.

    There are ongoing Phase 2 studies in Eastern Seaboard of the United States and also in the U.K., and those studies were small studies, again designed by Ridgeback to take doses based on Phase 1 and see both in the outpatient and inpatient setting, whether you could block by replication. So those studies are going on, date are being accrued, they're measuring viral production by repeated swabs and looking at the actual nucleic acid sequence of the virus. So we'll learn something from that, but the big Phase 2 studies and Phase 3 studies are just beginning. So very soon you'll see posted the large Phase 2 and then Phase 3 programs, which we will be initiating globally, and that will be happening within the next few weeks. I expect the enrollment will be fairly rapid, because unfortunately COVID-19 is very widespread, and so, they'll be both in the inpatient and outpatient setting, individuals with symptoms are eligible for treatment. We believe we have some understanding of where we need to be with respect to the dose. It is a five-day course of treatment, and the key question will be number one, do you knock down the virus, so that there is less of it? Number two, is that associated with clinical benefit?

    That should be visible fairly quickly. We have in discussions with regulatory agencies, particularly with FDA on the design of these studies. We've agreed on how they will work and how Phase 2 leads to Phase 3. The initial studies will enroll on the order of 2,000 or more subjects. So we'll get a lot of data, and the data will be extremely informative, and in the meantime, because we have a lot of confidence in the mechanism, [technical difficulty] manufacturing capability to produce tens of millions of doses by the end of the year. So, that's -- we're in a position to do a lot of good. I think it stands to reason that if we can say to the world that we can reduce the likelihood if you were in fact, we can reduce the likelihood that you would be hospitalized or certainly end up in intensive care unit, that would have a big effect on the psyche of the world, certainly in the United States, but elsewhere as well. We've ha
  • s
    stocktargetadvisor
    $MRK
    Target Set by JPMorgan Chase Neutral EUR 130
  • G
    Gary
    US pharma giant Merck is working on an experimental antiviral pill (code named MK-4482) that is currently under investigation. International news reports have suggested that if one goes by the results from mid-stage studies, there is a possibility that the medicine may reach the market before the year ends. Kenneth Frazier, chairman of the board and CEO of Merck, clarified that one study was checking the effect of the molecule on mild Covid-19 patients, while a separate study was on for hospitalised patients. The results from phase 2 trials are expected soon.

    https://www.business-standard.com/article/health/innovative-therapy-for-coronavirus-is-required-as-much-as-a-vaccine-120090400019_1.html
    Pharma giants have already started work on different formulations and combination therapies of their existing molecules
    Pharma giants have already started work on different formulations and combination therapies of their existing molecules
    www.business-standard.com
  • S
    SWISSQUOTEE
    Have a look to Agenus. AGEN
    Agenus New Data of her products (anti-PD-1 + anti-CTLA) are better as Keytruda
  • J
    Joe
    Merck begins human testing on their Covid 19 vaccine!
  • H
    HMG
    Merck to. begin covid 19 testing on humans. ~CNBC
  • A
    Anonymous
    Should I buy MRK for its coming dividend? I would rather buy PFE.
  • G
    Gary
    Merck is nearing the end of a years-long effort to dethrone Pfizer's megablockbuster pneumococcal conjugate vaccine, Prevnar 13. Straying away from its cash cow Keytruda, the NJ-based biotech says it will apply to license its candidate V114, which be
    Merck is nearing the end of a years-long effort to dethrone Pfizer's megablockbuster pneumococcal conjugate vaccine, Prevnar 13. Straying away from its cash cow Keytruda, the NJ-based biotech says it will apply to license its candidate V114, which be
    endpts.com
  • M
    Mike
    When will MRK announce MK-4482 phase 2 data? Anyone knows?
  • T
    The Chewdog
    Can we look forward to some of that newly minted tech money rotating into some of the blue chips like MRK?
    What do you think?
  • B
    B
    MRK: LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
  • A
    Anonymous
    Go ahead Merck. I know you want SGEN....here's the deal: three of your shares for each share of SGEN. I know it's a 70% premium over Friday's close and values SGEN at $44-45 B....but, compared to IMMU being taken out by GILD for $21 B, it's a great deal. Maybe SGEN would want more....but I think this would be a fair deal....today.
  • B
    B
    Golden Cross MRK let’s go for Joe!
  • B
    Brent
    MRK has no reason being sold down today. Buy the dippers.
  • G
    Gary
    Once results of MK-4482 Phase 2 studies are out, there will be a frenzy by hedge funds to buy back in, driving the price of MRK north of $90. Next month MRK is starting Phase 3 studies + NDA to FDA...
  • a
    adel
    Merck is good choice I think will see $95 Soon
  • G
    George
    Merck's MK-4482 stops coronavirus from replicating. It was discovered by Emory University scientists & results of phase 2 trials are expected in weeks.
    Merck's MK-4482 stops coronavirus from replicating. It was discovered by Emory University scientists & results of phase 2 trials are expected in weeks.
    theprint.in
  • S
    S197
    Next stop 89 and then back to previous highs?
  • D
    Daniel
    Barron's just named Merck it's stock pick of the week!
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more